NVCR250117C41000
- 0.00
- 0.000.00%
Novocure Newsroom
NovoCure Opens New Global Headquarters in Switzerland
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
Investing in NovoCure (NASDAQ:NVCR) a Year Ago Would Have Delivered You a 85% Gain
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $42
NovoCure (NVCR) Gets a Buy From Piper Sandler
Insider Sale: Chief Operating Officer of $NVCR (NVCR) Sells 2,160 Shares
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $40
NovoCure's Strong U.S. Revenue and European Growth Reinforce Buy Rating Despite Mixed Regional Performance
Novocure Reports Preliminary Net Revenues For Q4 Of $161.3M, Up 21% YoY Compared To Consensus Of $153.052M
Press Release: Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Novocure 4Q Rev $161M >NVCR
Express News | Novocure Ltd: Preliminary Full Year 2024 Net Revenues of $605 Mln and Q4 Net Revenues of $161 Mln
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Investors in NovoCure (NASDAQ:NVCR) Have Seen Notable Returns of 97% Over the Past Year
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46
Novocure Price Target Raised to $46 From $34 at Evercore ISI